{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:01:24Z","timestamp":1794715284580,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine symptoms, improve function, and enhance quality of life. Atogepant is a migraine-specific oral calcitonin gene\u2013related peptide receptor antagonist that is indicated for the preventive treatment of migraine in adults. This analysis evaluated the safety and tolerability profile of atogepant for the preventive treatment of migraine, including adverse events (AEs) of interest, such as constipation, nausea, hepatic safety, weight changes, and cardiac disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis was performed using data pooled from 2 (12-week) randomized, double-blind, placebo-controlled trials (RCTs) and 2 (40- and 52-week) open-label long-term safety (LTS) trials of oral atogepant for episodic migraine (EM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The safety population included 1550 participants from the pooled RCTs (atogepant,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091142; placebo,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009408) and 1424 participants from the pooled LTS trials (atogepant,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091228; standard care [SC],\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009196). In total, 643\/1142 (56.3%) atogepant participants and 218\/408 (53.4%) placebo participants experienced\u2009\u2265\u20091 treatment-emergent AEs (TEAEs) in the RCTs. In the LTS trials, 792\/1228 (64.5%) of atogepant participants and 154\/196 (78.6%) of SC participants experienced\u2009\u2265\u20091 TEAEs. The most commonly reported TEAEs (\u2265\u20095%) in participants who received atogepant once daily were upper respiratory tract infection (5.3% in RCTs, 7.7% in LTS trials), constipation (6.1% in RCTs, 5.0% in LTS trials), nausea (6.6% in RCTs, 4.6% in LTS trials), and urinary tract infection (3.4% in RCTs, 5.2% in LTS trials). Additionally, weight loss appeared to be dose- and duration-dependent. Most TEAEs were considered unrelated to study drug and few led to discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, atogepant is safe and well tolerated in pooled RCTs and LTS trials for the preventive treatment of EM in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifiers: NCT02848326 (MD-01), NCT03777059 (ADVANCE), NCT03700320 (study 302), NCT03939312 (study 309).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-024-01736-z","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T20:03:36Z","timestamp":1710101016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Paul","family":"Rizzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Marmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Robblee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McVige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De Abreu Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Dabruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"1736_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383:1866\u20131876","journal-title":"N Engl J Med"},{"key":"1736_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039","journal-title":"Headache"},{"key":"1736_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59:1\u201318","journal-title":"Headache"},{"key":"1736_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501\u2013514","journal-title":"Nat Rev Neurol"},{"key":"1736_CR5","volume-title":"AbbVie","author":"Qulipta","year":"2023","unstructured":"Qulipta (2023) AbbVie"},{"key":"1736_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K et al (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19:727\u2013737","journal-title":"Lancet Neurol"},{"key":"1736_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706","journal-title":"N Engl J Med"},{"key":"1736_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J et al (2023) Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial. Headache 63:79\u201388","journal-title":"Headache"},{"key":"1736_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/0333102418768095","volume":"39","author":"R Messina","year":"2019","unstructured":"Messina R, Goadsby PJ (2019) CGRP\u2014a target for acute therapy in migraine: clinical data. Cephalalgia 39:420\u2013427","journal-title":"Cephalalgia"},{"key":"1736_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1517\/13543784.2012.681044","volume":"21","author":"A Negro","year":"2012","unstructured":"Negro A, Lionetto L, Simmaco M, Martelletti P (2012) CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 21:807\u2013818","journal-title":"Expert Opin Investig Drugs"},{"key":"1736_CR11","first-page":"e1897","volume":"99","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM (2022) Blood pressure in patients with migraine treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study. Neurology 99:e1897\u2013e1904","journal-title":"Neurology"},{"key":"1736_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11916-022-01064-4","volume":"26","author":"J Robblee","year":"2022","unstructured":"Robblee J, Harvey LK (2022) Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep 26:647\u2013655","journal-title":"Curr Pain Headache Rep"},{"key":"1736_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s10194-020-01163-w","volume":"21","author":"ES Kristoffersen","year":"2020","unstructured":"Kristoffersen ES, B\u00f8rte S, Hagen K, Zwart JA, Winsvold BS (2020) Migraine, obesity and body fat distribution\u2014a population-based study. J Headache Pain 21:97","journal-title":"J Headache Pain"},{"key":"1736_CR14","doi-asserted-by":"publisher","first-page":"333102422112825","DOI":"10.1177\/03331024221128250","volume":"43","author":"BC Klein","year":"2023","unstructured":"Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J et al (2023) Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia 43:3331024221128250","journal-title":"Cephalalgia"},{"key":"1736_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"1736_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402:775\u2013785","journal-title":"Lancet"},{"key":"1736_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H et al (2022) Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia 42:3\u201311","journal-title":"Cephalalgia"},{"key":"1736_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-021-01227-5","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V et al (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22:16","journal-title":"J Headache Pain"},{"key":"1736_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","volume":"23","author":"C Lampl","year":"2022","unstructured":"Lampl C, Kraus V, Lehner K, Loop B, Chehrenama M, Maczynska Z et al (2022) Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials. J Headache Pain 23:104","journal-title":"J Headache Pain"},{"key":"1736_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350","journal-title":"Nat Rev Neurol"},{"issue":"suppl 1","key":"1736_CR21","first-page":"119","volume":"62","author":"AM Blumenfeld","year":"2022","unstructured":"Blumenfeld AM, Pavlovic JM, Harriott A, Best PJ, Monteith T, Ferreira R et al (2022) Post-hoc analysis evaluating safety of atogepant in ADVANCE & open-label extension participants with cardiovascular risk factors [abstract P-137]. Headache 62(suppl 1):119","journal-title":"Headache"},{"key":"1736_CR22","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798\u20131808","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01736-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T20:03:48Z","timestamp":1710101028000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01736-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1736"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01736-z","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All trials were performed in compliance with the International Conference on Harmonisation E6 Guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. Each investigator obtained approval from an independent ethics committee or a local institutional review board. Before administration of any study procedures, participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PR reports no relevant disclosures. MJM within the past 24\u00a0months, has received compensation for consultation from Alder\/Lundbeck, Axsome, Satsuma, Supernus, and Theranica; has participated in speaker bureaus for Amgen\/Novartis and Eli Lilly; has received institutional support for serving as principal investigator for Allergan\/AbbVie, and Teva; and has received payments for authorship or royalties from Cambridge University Press, Demos Medical, and MedLink. JR has received grant support from Barrow Neurological Foundation and investigator support from AbbVie and Eli Lilly; has served as a speaker for Impel; has a paid editorial relationship with MedLink Neurological and Neurodiem; and discloses that a family member has partial ownership of Scottsdale Providence Recovery Center. JM has served as a speaker and\/or received research support from Alder, Allergan (now AbbVie), Amgen\/Novartis, Avanir, Biohaven, Eli Lilly, Lundbeck, and Teva. SS has participated in advisory boards and\/or is a speaker for Allergan (now AbbVie), Amgen, BDSI, Biohaven, Eli Lilly, Impel NeuroPharma, and Teva. SJN has received honoraria for consulting from Alder\/Lundbeck, Allergan\/AbbVie, Axsome (ended January 2022), BioDelivery Sciences (ended February 2022), Biohaven (ended November 2021), Eli Lilly, Teva (ended October 2021), Theranica (ended September 2022); has received honoraria for speaking from Eli Lilly (ended September 2021); has received honoraria for work in education or publishing from American Academy of Neurology, American Headache Society, Evolve Med Ed, Massachusetts Medical Society, MedLink Neurology, MJH Life Sciences, NACCME, Neurology Learning Network, Pennsylvania Neurologic Society, Springer, WebMD\/Medscape, Wolters-Kluwer; has received legal fees for serving as a medical expert to Jackson & Campbell. JA has served as a consultant for AbbVie, Aeon, Amgen, Biohaven, Eli Lilly, GlaxoSmithKline, Gore, Impel, Linpharma, Lundbeck, Miravo, Nesos, Neurolief, Pfizer, Satsuma, Teva, and Theranica; received stock options from Ctrl M; provided editorial services to <i>Current Pain and Headache Reports<\/i>, SELF, and Medscape; and received clinical trial support from AbbVie, Biohaven, Eli Lilly, Rehaler, Satsuma, and Zosano. RDF, JM, JHS, and BD are employees of AbbVie and may hold AbbVie stock. MA has received personal fees from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer and Teva; has participated in clinical trials as the principal investigator for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva; has received research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; serves as associate editor of <i>Cephalalgia<\/i>, associate editor of <i>The Journal of Headache and Pain<\/i>, and associate editor of <i>Brain<\/i>; and has no ownership interest and does not own stocks of any pharmaceutical company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}